Common variation in the NOS1AP gene is associated with reduced glucose-lowering effect and with increased mortality in users of sulfonylurea

Pharmacogenetics and Genomics

Volumn 18, Issue 7, 2008, Pages 591-597

  Becker, Matthijs L ^a   Aarnoudse, Albert Jan L H J ^a,b   Newton Cheh, Christopher ^c,d   Hofman, Albert ^a   Witteman, Jacqueline C M ^a   Uitterlinden, André G ^a   Visser, Loes E ^a   Stricker, Bruno H Ch ^a,b  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b Drug Safety Unit   (Netherlands)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

Diabetes mellitus; Nitric oxide synthase; Sulfonylurea compounds; Type 2

Indexed keywords

ADAPTOR PROTEIN; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; GLUCOSE; INSULIN; METFORMIN; NITRIC OXIDE SYNTHASE 1 ADAPTOR PROTEIN; TOLBUTAMIDE; UNCLASSIFIED DRUG; ANTIDIABETIC AGENT; NOS1AP PROTEIN, HUMAN; SIGNAL TRANSDUCING ADAPTOR PROTEIN; SULFONYLUREA DERIVATIVE;

AGED; ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EFFECT; FEMALE; FOLLOW UP; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; GLUCOSE BLOOD LEVEL; GROUPS BY AGE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; POPULATION RESEARCH; PRESCRIPTION; PRIORITY JOURNAL; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; DRUG RESISTANCE; GENETICS; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; SURVIVAL;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; AGED; AGED, 80 AND OVER; BLOOD GLUCOSE; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; DRUG RESISTANCE; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; SULFONYLUREA COMPOUNDS; SURVIVAL ANALYSIS;

EID: 53049096127     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0b013e328300e8c5     Document Type: Article

References (37)

1. Klimt CR, Knatterud GL, Meinert CL, Prout TE. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. Diabetes 1970; 19 (Suppl):747-830.
2. Schor S. The University Group Diabetes Program: a statistician looks at the mortality results. J Am Med Assoc 1971; 217:1671-1675.
3. Seltzer HS. A summary of criticisms of the findings and conclusions of the University Group Diabetes Program (UGDP). Diabetes 1972; 21:976-979.
4. Cornfield J. The University Group Diabetes Program: a further statistical analysis of the mortality findings. J Am Med Assoc 1971; 217:1676-1687.
5. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352:837-853.
6. Ashcroft FM, Rorsman P. Electrophysiology of the pancreatic beta-cell. Prog Biophys Mol Biol 1989; 54:87-143.
7. Boyd AE, Aguilar-Bryan L, Nelson DA. Molecular mechanisms of action of glyburide on the beta cell. Am J Med 1990; 89 (Suppl 1):S3-S10.
8. Proks P, Reimann F, Green N, Gribble F, Ashcroft F. Sulfonylurea stimulation of insulin secretion. Diabetes 2002; 51 (Suppl):S368-S376.
9. Schulz R, Rassaf T, Massion PB, Kelm M, Balligand JL. Recent advances in the understanding of the role of nitric oxide in cardiovascular homeostasis. Pharmacol Ther 2005; 108:225-256.
10. Aarnoudse AJ, Newton-Cheh C, de Bakker PI, Straus SM, Kors JA, Hofman A, et al. Common NOS1AP variants are associated with a prolonged QTc interval in the Rotterdam Study. Circulation 2007; 116:10-16.
11. Arking DE, Pfeufer A, Post W, Kao WH, Newton-Cheh C, Ikeda M, et al. A common genetic variant in the NOS1 regulator NOS1AP modulates cardiac repolarization. Nat Genet 2006; 38:644-651.
12. PostW, Shen H, Damcott C, Arking DE, Kao WH, Sack PA, et al. Associations between genetic variants in the NOS1AP (CAPON) gene and cardiac repolarization in the old order Amish. Hum Hered 2007; 64:214-219.
13. Massion PB, Pelat M, Belge C, Balligand JL. Regulation of the mammalian heart function by nitric oxide. Comp Biochem Physiol A Mol Integr Physiol 2005; 142:144-150.
14. Lajoix AD, Reggio H, Chardes T, Peraldi-Roux S, Tribillac F, Roye M, et al. A neuronal isoform of nitric oxide synthase expressed in pancreatic beta-cells controls insulin secretion. Diabetes 2001; 50:1311-1323.
15. Gunawardana SC, Rocheleau JV, Head WS, Piston DW. Mechanisms of time-dependent potentiation of insulin release: involvement of nitric oxide synthase. Diabetes 2006; 55:1029-1033.
16. Hofman A, Grobbee DE, de Jong PT, van den Ouweland FA. Determinants of disease and disability in the elderly: the Rotterdam Elderly study. Eur J Epidemiol 1991; 7:403-422.
17. Hofman A, Breteler MM, van Duijn CM, Krestin GP, Pols HA, Stricker BH, et al. The Rotterdam Study: objectives and design update. Eur J Epidemiol 2007; 22:819-829.
18. World Health Organization. International statistical classification of diseases and related health problems. Tenth revision. Geneva: World Health Organization; 1992.
19. World Health Organization Collaborating Centre for Drug Statistics Methodology. Complete ATC index 2007; 2007. Available from http://www.whocc.no/ atcddd/indexdatabase. Accessed 30 October 2007.
20. Fang Y, van Meurs JB, d'Alesio A, Jhamai M, Zhao H, Rivadeneira F, et al. Promoter and 3′-untranslated-region haplotypes in the vitamin d receptor gene predispose to osteoporotic fracture: the Rotterdam study. Am J Hum Genet 2005; 77:807-823.
21. Yokoshiki H, Sunagawa M, Seki T, Sperelakis N. ATP-sensitive K+ channels in pancreatic, cardiac, and vascular smooth muscle cells. Am J Physiol 1998; 274:C25-C37.
22. Song DK, Ashcroft FM. Glimepiride block of cloned beta-cell, cardiac and smooth muscle K(ATP) channels. Br J Pharmacol 2001; 133: 193-199.
23. Dorschner H, Brekardin E, Uhde I, Schwanstecher C, Schwanstecher M. Stoichiometry of sulfonylurea-induced ATP-sensitive potassium channel closure. Mol Pharmacol 1999; 55:1060-1066.
24. Ashcroft FM, Gribble FM. Tissue-specific effects of sulfonylureas: lessons from studies of cloned K(ATP) channels. J Diabetes Complications 2000; 14:192-196.
25. Venkatesh N, Lamp ST, Weiss JN. Sulfonylureas, ATP-sensitive K+ channels, and cellular K+ loss during hypoxia, ischemia, and metabolic inhibition in mammalian ventricle. Circ Res 1991; 69:623-637.
26. Engler RL, Yellon DM. Sulfonylurea Katp blockade in type II diabetes and preconditioning in cardiovascular disease. Time for reconsideration. Circulation 1996; 94:2297-2301.
27. Brady PA, Terzic A. The sulfonylurea controversy: more questions from the heart. J Am Coll Cardiol 1998; 31:950-956.
28. Sattiraju S, Reyes S, Kane GC, Terzic A. K(ATP) channel pharmacogenomics: from bench to bedside. Clin Pharmacol Ther 2008; 83:354-357.
29. Garratt KN, Brady PA, Hassinger NL, Grill DE, Terzic A, Holmes DR. Sulfonylurea drugs increase early mortality in patients with diabetes mellitus after direct angioplasty for acute myocardial infarction. J Am Coll Cardiol 1999; 33:119-124.
30. Lee TM, Chou TF. Impairment of myocardial protection in type 2 diabetic patients. J Clin Endocrinol Metab 2003; 88:531-537.
31. Legtenberg RJ, Houston RJ, Oeseburg B, Smits P. Effects of sulfonylurea derivatives on ischemia-induced loss of function in the isolated rat heart. Eur J Pharmacol 2001; 419:85-92.
32. Mocanu MM, Maddock HL, Baxter GF, Lawrence CL, Standen NB, Yellon DM. Glimepiride, a novel sulfonylurea, does not abolish myocardial protection afforded by either ischemic preconditioning or diazoxide. Circulation 2001; 103:3111-3116.
33. Rosati B, Rocchetti M, Zaza A, Wanke E. Sulfonylureas blockade of neural and cardiac HERG channels. FEBS Lett 1998; 440:125-130.
34. Schaffer P, Pelzmann B, Bernhart E, Lang P, Machler H, Rigler B, et al. The sulphonylurea glibenclamide inhibits voltage dependent potassium currents in human atrial and ventricular myocytes. Br J Pharmacol 1999; 128:1175-1180.
35. Kanno T, Rorsman P, Gopel SO. Glucose-dependent regulation of rhythmic action potential firing in pancreatic beta-cells by K(ATP)-channel modulation. J Physiol 2002; 545:501-507.
36. Gopel SO, Kanno T, Barg S, Eliasson L, Galvanovskis J, Renstrom E, et al. Activation of Ca(2+)-dependent K(+) channels contributes to rhythmic firing of action potentials in mouse pancreatic beta cells. J Gen Physiol 1999; 114:759-770.
37. Bolotina VM, Najibi S, Palacino JJ, Pagano PJ, Cohen RA. Nitric oxide directly activates calcium-dependent potassium channels in vascular smooth muscle. Nature 1994; 368:850-853.